Adiponectin predicts cardiovascular events in diabetes dialysis patients

Abstract

ObjectivesAdiponectin is an insulin-sensitizing, anti-inflammatory adipokine with anti-atherogenic actions in the general population. In dialysis patients it is unclear whether adiponectin conserves its protective value or is, on the contrary, associated to worse prognosis. We assessed the predictive value of adiponectin for atherosclerosis related cardiovascular events in type 2 diabetic dialysis patients. Design and methodsPrevalent diabetic dialysis patients from three dialysis units (n=77) were enrolled in a 3years' prospective observational study. Serum adiponectin, clinical and laboratory parameters were determined at baseline; new occurrence of atherosclerosis related events (coronary events, atherosclerosis obliterans, and stroke) was recorded. ResultsBaseline adiponectin was 17.25(9.53–31.97) μg/mL and significantly correlated to HDL cholesterol (r=0.29, p=0.01), triglycerides (r=−0.40, p=0.0004), ferritin (r=−0.29, p=0.02), transferrin (r=−0.28, p=0.02), and uric acid (r=−0.24, p=0.04). In multivariate analysis association to triglycerides (p=0.001), HDL cholesterol (p=0.01) and ferritin (p=0.04) remained significant. 36 new fatal and non-fatal new cardiovascular events occurred, 29 patient died. Cox proportional regression analysis showed that adiponectin below or above a ROC-derived cut-off of 27.33μg/mL significantly influenced event-free survival: hazard ratio (HR) 2.48, 95% confidence interval (CI) (1.09–5.66), p=0.031 along with fasting glucose HR 1.01, 95%CI(1.00–1.02), p=0.01 and history of cardiovascular events at inclusion HR 3.16, 95%CI(1.36–7.32), p=0.007. In multivariate analysis baseline adiponectin HR 5.02, 95%CI(0.98–25.06), p=0.05 and glycemia HR 1.01, 95%CI(1.00–1.02), p=0.01 influenced event-free survival. Adiponectin also predicted cardiovascular events in patients without cardiovascular disease at inclusion but was not associated to overall mortality. ConclusionsIn diabetes dialysis patients low adiponectin favors occurrence of atherosclerosis related cardiovascular events.